ISSN: 2278-0238

Revue internationale de recherche et développement en pharmacie et sciences de la vie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Review: Recent Perspectives in Ocular Drug Delivery

Mr. Rahul S Khaire

The delivery of drugs to the eye has been a major challenge for pharmacologists due to the unique anatomy and physiology of the eye. Static barriers (various layers of the cornea, sclera, and retina, including aqueous and bloodretinal barriers), dynamic barriers (choroidal and conjunctival blood flow, lymphatic clearance, and tear dilution), and drip pumps. especially in the rear segment. The identification of impulse transporters on different ocular tissues and the design of a transporter-targeted parenteral drug delivery have gained momentum in recent years. In parallel, colloidal dosage forms such as nanoparticles, nanocells, liposomes, and micro emulsions have been extensively studied to overcome various static and dynamic barriers. Novel drug delivery strategies such as bioadhesive gels and fibrin glues have been developed to maintain drug levels at the target site. The development of non-invasive continuous drug delivery systems and research into the feasibility of local use for post-drug delivery could greatly improve drug delivery in the years to come. Recent developments in the field of ophthalmic drug delivery promise significant improvements in overcoming the challenges of various diseases of the anterior and posterior segments of the eye. A better understanding of the nature of ocular diseases, barriers, and factors affecting in vivo performance would significantly advance the development of new delivery systems. The current momentum in the invention of new drug delivery systems promises greatly improved therapies for the treatment of vision disorders.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.